Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

891471

registered interest
date	25/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Muscular Dystrophy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the suitability of the Single Technology Appraisal process for new treatments for patients with Duchenne Muscular Dystrophy.
tabling member constituency	Chesham and Amersham
tabling member printed	Dame Cheryl Gillan
uin	137885
answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources.</p><p> </p><p>NICE assesses most significant new drugs through its technology appraisal programme and has been able to recommend a number of drugs licenced for the treatment of rare diseases for routine use on the NHS. NICE also operates a separate highly specialised technology (HST) evaluation programme for the assessment of very high cost drugs for the treatment of very small numbers of patients. Decisions on the most appropriate programme for individual drugs and other treatments are made through an established topic selection process that includes a public consultation and thorough consideration against a set of published criteria.</p><p> </p><p>NICE published HST guidance recommending ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in July 2016 and is currently developing guidance, through its technology appraisal and HST programmes, on other drugs for the treatment of Duchenne muscular dystrophy.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/05/2018 15:58:20 answering member 4067 label Biography information for Steve Brine
tabling member	18 label Biography information for Dame Cheryl Gillan

891478

registered interest
date	25/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of increasing flexibility within NICE's Single Technology Appraisal process for medicines for rare diseases.
tabling member constituency	Chesham and Amersham
tabling member printed	Dame Cheryl Gillan
uin	137886
answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>The Department has made no such assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the NHS on whether drugs and other treatments represent an effective use of National Health Service resources.</p><p> </p><p>NICE assesses most significant new drugs through its technology appraisal programme and has been able to recommend a number of drugs licenced for the treatment of rare diseases for routine use on the NHS. NICE also operates a separate highly specialised technology evaluation programme for the assessment of very high cost drugs for the treatment of very small numbers of patients.</p><p> </p><p>NICE’s methods and processes for the assessment of drugs have been carefully developed over time and are internationally respected. NICE continues to keep its procedures under periodic review to ensure that they remain effective.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/05/2018 13:21:07 answering member 4067 label Biography information for Steve Brine
tabling member	18 label Biography information for Dame Cheryl Gillan

891482

registered interest
date	25/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pregnancy: Sodium Valproate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what representations his Department and its agencies have received on the resources necessary to improve patient safety and engage with health professionals to raise awareness of the potential health risks for women of child-bearing age taking Sodium Valproate; and if he will make a statement.
tabling member constituency	Chesham and Amersham
tabling member printed	Dame Cheryl Gillan
uin	137887
answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is working in partnership with the Department, professional bodies and the healthcare system to deliver a package of measures to raise awareness of the significant risks associated with sodium valproate in pregnancy and to support healthcare professionals in reducing the harms from valproate in women of child-bearing age and improving patient safety in line with the strengthened regulatory position. Educational materials for healthcare professionals and patients are being sent to general practitioners (GP) and specialist prescribers. The National Institute for Health and Care Excellence has updated its guidelines which mention valproate to reflect the new regulatory measures. GP electronic system providers have provided a search and audit function to facilitate the identification of women of childbearing age on valproate and are updating the alerts for valproate.</p><p> </p><p>All parties involved are fully committed to this important work using the resources available from each relevant organisation. In addition, since 2016 the MHRA has been working with a network of over 40 stakeholder organisations (termed the Valproate Stakeholders’ Network) to foster cross-sector support for the new measures and leverage their collective communications reach.</p><p> </p><p>The effectiveness of the new measures in reducing prescribing of valproate in women of childbearing potential will be closely monitored. Relevant data will be published and there will be ongoing follow-up to ensure that the harms to the child from valproate in pregnancy are minimised.</p><p> </p><p>I would particularly like to thank the families involved in the Valproate Stakeholder Network who have shared their experiences and expertise. Their dedication, support and altruism will help to keep future generations of children safe.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 03/05/2018 12:59:46 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	18 label Biography information for Dame Cheryl Gillan